BioNumerik Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1992-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://bionumerik.com
Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin
Phase 3
Completed
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Drug: Placebo in combination with cisplatin and docetaxel or paclitaxelDrug: Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel
- First Posted Date
- 2009-08-27
- Last Posted Date
- 2022-07-13
- Lead Sponsor
- BioNumerik Pharmaceuticals, Inc.
- Target Recruit Count
- 540
- Registration Number
- NCT00966914
Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer
- First Posted Date
- 2007-05-23
- Last Posted Date
- 2020-03-12
- Lead Sponsor
- BioNumerik Pharmaceuticals, Inc.
- Target Recruit Count
- 509
- Registration Number
- NCT00477282
Trial of Oral Karenitecin in Patients With Solid Tumors and Lung Cancer
Phase 1
Completed
- Conditions
- CarcinomaCarcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2004-12-02
- Last Posted Date
- 2020-03-12
- Lead Sponsor
- BioNumerik Pharmaceuticals, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT00097903
- Locations
- 🇺🇸
Ellis Fischel Cancer Center, Columbia, Missouri, United States
Study of Karenitecin (BNP1350) to Treat Malignant Melanoma
- First Posted Date
- 2003-06-12
- Last Posted Date
- 2020-03-12
- Lead Sponsor
- BioNumerik Pharmaceuticals, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT00062491
- Locations
- 🇺🇸
For Information call 210-614-1701 for a site near you, Tampa, Florida, United States
Study of Karenitecin (BNP1350) in Patients With Brain Tumors
Phase 2
Completed
- Conditions
- Brain NeoplasmsMalignant Neoplasms, BrainBrain Tumors
- Interventions
- First Posted Date
- 2003-06-12
- Last Posted Date
- 2020-03-12
- Lead Sponsor
- BioNumerik Pharmaceuticals, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT00062478
- Locations
- 🇺🇸
For Information call 210-614-1701 for a site near you, Durham, North Carolina, United States
Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel
Phase 3
Completed
- Conditions
- Breast NeoplasmsMetastases, NeoplasmBreast Diseases
- Interventions
- Drug: Placebo
- First Posted Date
- 2002-06-13
- Last Posted Date
- 2022-07-13
- Lead Sponsor
- BioNumerik Pharmaceuticals, Inc.
- Target Recruit Count
- 764
- Registration Number
- NCT00039780
© Copyright 2025. All Rights Reserved by MedPath